Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-03-01
1990-12-25
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 15, C07D51320, C07D49820, A61K 31395
Patent
active
049803573
ABSTRACT:
A series of novel spiro-deteroazolones derived from a 2,3-dihydropryrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxazolidinediones, spiro-thiazolidinediones and spiro-imidazolidinediones derived from the aforesaid ring system. (4'S) (2'R)-6'-Chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-pyra no[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.
REFERENCES:
patent: 3821383 (1974-09-01), Sestanj et al.
patent: 4117230 (1978-09-01), Sarges
patent: 4130714 (1978-12-01), Sarges
Goldstein Steven W.
Sarges Reinhard
Bond Robert T.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Azolidinedione derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azolidinedione derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azolidinedione derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1162948